Treatment patterns and overall survival among patients with unresectable, stage III non-small-cell lung cancer

Priyanka Bobbili; Kellie Ryan; Mei S. Duh; Akanksha Dua; Ancilla W. Fernandes; Melissa Pavilack; Jorge E. Gomez

doi:10.2217/fon-2019-0282

Treatment patterns and overall survival among patients with unresectable, stage III non-small-cell lung cancer

Priyanka Bobbili, Kellie Ryan, Mei S. Duh, Akanksha Dua, Ancilla W. Fernandes, Melissa Pavilack, Jorge E. Gomez

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Aim: To analyze treatment patterns and overall survival (OS) across time (2009-2014) among patients with unresected, stage III non-small-cell lung cancer (NSCLC). Patients & methods: Stage III NSCLC patients aged ≥65 years who initiated therapy were identified using SEER-Medicare data. Results: Among 4564 patients, 84% received chemotherapy (with or without radiotherapy), and 59% received chemoradiotherapy (CRT). Carboplatin + paclitaxel was the most frequent regimen. Median (interquartile range) OS among chemotherapy patients was 13.2 (6.0-28.9) months, and 14.8 (6.7-33.4) months among CRT patients. Among CRT patients, there was no difference in OS across years of CRT initiation. Conclusion: OS remained static across 2009-2014, indicating stagnancy in clinical outcomes for stage III NSCLC patients and a need for more effective therapeutic options.

Original language	English
Pages (from-to)	3381-3393
Number of pages	13
Journal	Future Oncology
Volume	15
Issue number	29
DOIs	https://doi.org/10.2217/fon-2019-0282
State	Published - 2019

Keywords

chemoradiotherapy
chemotherapy
medicare
multi-modality SEER-medicare
standard-of-care

Access to Document

10.2217/fon-2019-0282

Cite this

@article{cb6bc824d34948dcad75b47c66e41b18,

title = "Treatment patterns and overall survival among patients with unresectable, stage III non-small-cell lung cancer",

abstract = "Aim: To analyze treatment patterns and overall survival (OS) across time (2009-2014) among patients with unresected, stage III non-small-cell lung cancer (NSCLC). Patients & methods: Stage III NSCLC patients aged ≥65 years who initiated therapy were identified using SEER-Medicare data. Results: Among 4564 patients, 84% received chemotherapy (with or without radiotherapy), and 59% received chemoradiotherapy (CRT). Carboplatin + paclitaxel was the most frequent regimen. Median (interquartile range) OS among chemotherapy patients was 13.2 (6.0-28.9) months, and 14.8 (6.7-33.4) months among CRT patients. Among CRT patients, there was no difference in OS across years of CRT initiation. Conclusion: OS remained static across 2009-2014, indicating stagnancy in clinical outcomes for stage III NSCLC patients and a need for more effective therapeutic options.",

keywords = "chemoradiotherapy, chemotherapy, medicare, multi-modality SEER-medicare, standard-of-care",

author = "Priyanka Bobbili and Kellie Ryan and Duh, {Mei S.} and Akanksha Dua and Fernandes, {Ancilla W.} and Melissa Pavilack and Gomez, {Jorge E.}",

note = "Publisher Copyright: {\textcopyright} 2019 Kellie Ryan.",

year = "2019",

doi = "10.2217/fon-2019-0282",

language = "English",

volume = "15",

pages = "3381--3393",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Taylor and Francis Ltd.",

number = "29",

}

TY - JOUR

T1 - Treatment patterns and overall survival among patients with unresectable, stage III non-small-cell lung cancer

AU - Bobbili, Priyanka

AU - Ryan, Kellie

AU - Duh, Mei S.

AU - Dua, Akanksha

AU - Fernandes, Ancilla W.

AU - Pavilack, Melissa

AU - Gomez, Jorge E.

PY - 2019

Y1 - 2019

N2 - Aim: To analyze treatment patterns and overall survival (OS) across time (2009-2014) among patients with unresected, stage III non-small-cell lung cancer (NSCLC). Patients & methods: Stage III NSCLC patients aged ≥65 years who initiated therapy were identified using SEER-Medicare data. Results: Among 4564 patients, 84% received chemotherapy (with or without radiotherapy), and 59% received chemoradiotherapy (CRT). Carboplatin + paclitaxel was the most frequent regimen. Median (interquartile range) OS among chemotherapy patients was 13.2 (6.0-28.9) months, and 14.8 (6.7-33.4) months among CRT patients. Among CRT patients, there was no difference in OS across years of CRT initiation. Conclusion: OS remained static across 2009-2014, indicating stagnancy in clinical outcomes for stage III NSCLC patients and a need for more effective therapeutic options.

AB - Aim: To analyze treatment patterns and overall survival (OS) across time (2009-2014) among patients with unresected, stage III non-small-cell lung cancer (NSCLC). Patients & methods: Stage III NSCLC patients aged ≥65 years who initiated therapy were identified using SEER-Medicare data. Results: Among 4564 patients, 84% received chemotherapy (with or without radiotherapy), and 59% received chemoradiotherapy (CRT). Carboplatin + paclitaxel was the most frequent regimen. Median (interquartile range) OS among chemotherapy patients was 13.2 (6.0-28.9) months, and 14.8 (6.7-33.4) months among CRT patients. Among CRT patients, there was no difference in OS across years of CRT initiation. Conclusion: OS remained static across 2009-2014, indicating stagnancy in clinical outcomes for stage III NSCLC patients and a need for more effective therapeutic options.

KW - chemoradiotherapy

KW - chemotherapy

KW - medicare

KW - multi-modality SEER-medicare

KW - standard-of-care

UR - http://www.scopus.com/inward/record.url?scp=85073763973&partnerID=8YFLogxK

U2 - 10.2217/fon-2019-0282

DO - 10.2217/fon-2019-0282

M3 - Article

C2 - 31544510

AN - SCOPUS:85073763973

SN - 1479-6694

VL - 15

SP - 3381

EP - 3393

JO - Future Oncology

JF - Future Oncology

IS - 29

ER -

Treatment patterns and overall survival among patients with unresectable, stage III non-small-cell lung cancer

Abstract

Keywords

Access to Document

Fingerprint

Cite this